According to the company, the U.S. Food and Drug Administration has given nod for its abbreviated new drug application to the product and it is all ready to go. The company added that these products are meant for hypertension in patients not adequately controlled with either single drug therapy agent and falls under the cardiovascular to treat therapeutic category.

Peer-reviewed journal peer-reviewed journal for research at the interface of law, health policy, ethics and medicine, Journal of Law have created a involved the authoritative source for health law teachers, practitioners, policy makers, risk managers, and anyone with a safe, just and ethical delivery and promotion of public health. For more information, please visit.About Parkinson Psychosis According to the National Parkinson Foundation, over 1.5 million people the United States suffering from Parkinson’s disease. Can be developing to 40 % of people with Parkinson disease psychotic symptoms are, frequent consisting of visual hallucinations and delusions. There are currently no permitted treatment to treat it in the U.S. PDP. Developing of psychosis to patients with PD is associated with a higher caregiver burden, nursing homes , and increased mortality. This program is free of charge until 30 April 2011 are available. To register or for more information visit here.

Source: SN.

The phase III study, a multicenter, double-blind, placebo-controlled trial to evaluate the safety and efficacy of Pimavanserin patients with a with PDP. Of 298 patients enrolled into the study and randomized to one of three study arms including two different doses of Pimavanserin and one placebo arm. Patients obtained doses of either oral Pimavanserin and placebo once daily for six weeks addition to a stable dose from of your current dopamine replacement therapy.

Other articles from category "pharmacy news":

Random articles